Upbeat On Injectables, Aurobindo Hiking Capacities
Acquisition In Emerging Markets Possible
Executive Summary
Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.
You may also be interested in...
Aurobindo Expects Interim Phase II/III COVID-19 Vaccine Data By July
Aurobindo expects the first data readouts from the Phase II/III clinical trials of its partnered COVID-19 vaccine by July. While making progress in biosimilars development, the Indian company also plans to invest substantially in new API capacity.
Indian Alliance For Pfizer/BioNTech’s COVID-19 Vaccine?
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.
Aurobindo Eyes Opportunities After Offloading Natrol For $550m
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.